Mounjaro · Zepbound
Dual GIP/GLP-1 agonist — superior weight loss to semaglutide.
FDA
Approved
WADA
Not Listed
HALF-LIFE
5 days
ROUTE
SubQ injection (weekly)
SCHEDULE
Once weekly
In Plain English
Dual GIP/GLP-1 agonist — superior weight loss to semaglutide.
Status & Legality
What do these mean?Weight loss
Type 2 diabetes
Metabolic health
Tirzepatide targets both GLP-1 and GIP receptors, making it the first dual incretin receptor agonist approved for weight management. Clinical trials showed up to 22.5% body weight reduction — the highest of any approved therapeutic — with additional benefits in cardiovascular risk markers and sleep apnea.
Nausea
Diarrhea
Vomiting
Constipation
Decreased appetite
Abdominal pain
Injection site reactions
Jumping dose escalations — tirzepatide is more potent than semaglutide; the same rushed titration causes more severe GI effects
Not tracking protein intake — muscle loss at the weight loss rates tirzepatide achieves is significant without active intervention
Stopping abruptly without a maintenance plan — weight regain is rapid; plan the transition before reaching goal weight
Insulin and sulfonylureas — significant hypoglycemia risk; reduce doses when starting
Oral medications — slowed gastric emptying affects absorption timing and peak blood levels
Warfarin — monitor INR more closely during active weight loss and dose changes
Tirzepatide's 22.5% average weight loss in trials puts it in a different category than semaglutide. The dual GIP/GLP-1 mechanism makes it more potent but GI side effects are more intense at escalating doses. The creatine + high protein rule is more critical here, not less — the faster the weight loss, the more muscle you risk losing.
GHK-CU
Anti-aging copper peptide — skin, hair, collagen, and wound repair.
SEMAGLUTIDE
FDA-approved GLP-1 agonist — weight loss and blood sugar control.
LIRAGLUTIDE
Daily GLP-1 agonist — the original injectable for weight loss.
Free, no account needed
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepvault.us to opt out any time.
Stats
Sources & Studies
Jastreboff AM. et al., N Engl J Med, 2022